CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium
13. Februar 2020 09:15 ET
|
CicloMed LLC
First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patientsInitiation of fosciclopirox...